L S Hu1, Z Kelm2, P Korfiatis2, A C Dueck3, C Elrod4, B M Ellingson5, T J Kaufmann2, J M Eschbacher6, J P Karis7, K Smith8, P Nakaji8, D Brinkman9, D Pafundi9, L C Baxter4, B J Erickson2. 1. From the Department of Radiology (L.S.H.) Keller Center for Imaging Innovation (L.S.H., C.E., J.P.K., L.C.B.) Hu.Leland@Mayo.Edu. 2. the Department of Radiology (Z.K., P.K., T.J.K., B.J.E.), Mayo Clinic, Rochester, Minnesota. 3. Biostatistics (A.C.D.), Mayo Clinic, Phoenix/Scottsdale, Arizona. 4. Keller Center for Imaging Innovation (L.S.H., C.E., J.P.K., L.C.B.). 5. the Department of Radiological Sciences (B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, California. 6. Departments of Neuropathology (J.M.E.). 7. Keller Center for Imaging Innovation (L.S.H., C.E., J.P.K., L.C.B.) Neuroradiology (J.P.K.). 8. Neurosurgery (K.S., P.N.), Barrow Neurological Institute, Phoenix, Arizona. 9. the Department of Radiation Oncology (D.B., D.P.), Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND AND PURPOSE: Relative cerebral blood volume, as measured by T2*-weighted dynamic susceptibility-weighted contrast-enhanced MRI, represents the most robust and widely used perfusion MR imaging metric in neuro-oncology. Our aim was to determine whether differences in modeling implementation will impact the correction of leakage effects (from blood-brain barrier disruption) and the accuracy of relative CBV calculations as measured on T2*-weighted dynamic susceptibility-weighted contrast-enhanced MR imaging at 3T field strength. MATERIALS AND METHODS: This study included 52 patients with glioma undergoing DSC MR imaging. Thirty-six patients underwent both non-preload dose- and preload dose-corrected DSC acquisitions, with 16 patients undergoing preload dose-corrected acquisitions only. For each acquisition, we generated 2 sets of relative CBV metrics by using 2 separate, widely published, FDA-approved commercial software packages: IB Neuro and nordicICE. We calculated 4 relative CBV metrics within tumor volumes: mean relative CBV, mode relative CBV, percentage of voxels with relative CBV > 1.75, and percentage of voxels with relative CBV > 1.0 (fractional tumor burden). We determined Pearson (r) and Spearman (ρ) correlations between non-preload dose- and preload dose-corrected metrics. In a subset of patients with recurrent glioblastoma (n = 25), we determined receiver operating characteristic area under the curve for fractional tumor burden accuracy to predict the tissue diagnosis of tumor recurrence versus posttreatment effect. We also determined correlations between rCBV and microvessel area from stereotactic biopsies (n = 29) in 12 patients. RESULTS: With IB Neuro, relative CBV metrics correlated highly between non-preload dose- and preload dose-corrected conditions for fractional tumor burden (r = 0.96, ρ = 0.94), percentage > 1.75 (r = 0.93, ρ = 0.91), mean (r = 0.87, ρ = 0.86), and mode (r = 0.78, ρ = 0.76). These correlations dropped substantially with nordicICE. With fractional tumor burden, IB Neuro was more accurate than nordicICE in diagnosing tumor versus posttreatment effect (area under the curve = 0.85 versus 0.67) (P < .01). The highest relative CBV-microvessel area correlations required preload dose and IB Neuro (r = 0.64, ρ = 0.58, P = .001). CONCLUSIONS: Different implementations of perfusion MR imaging software modeling can impact the accuracy of leakage correction, relative CBV calculation, and correlations with histologic benchmarks.
BACKGROUND AND PURPOSE: Relative cerebral blood volume, as measured by T2*-weighted dynamic susceptibility-weighted contrast-enhanced MRI, represents the most robust and widely used perfusion MR imaging metric in neuro-oncology. Our aim was to determine whether differences in modeling implementation will impact the correction of leakage effects (from blood-brain barrier disruption) and the accuracy of relative CBV calculations as measured on T2*-weighted dynamic susceptibility-weighted contrast-enhanced MR imaging at 3T field strength. MATERIALS AND METHODS: This study included 52 patients with glioma undergoing DSC MR imaging. Thirty-six patients underwent both non-preload dose- and preload dose-corrected DSC acquisitions, with 16 patients undergoing preload dose-corrected acquisitions only. For each acquisition, we generated 2 sets of relative CBV metrics by using 2 separate, widely published, FDA-approved commercial software packages: IB Neuro and nordicICE. We calculated 4 relative CBV metrics within tumor volumes: mean relative CBV, mode relative CBV, percentage of voxels with relative CBV > 1.75, and percentage of voxels with relative CBV > 1.0 (fractional tumor burden). We determined Pearson (r) and Spearman (ρ) correlations between non-preload dose- and preload dose-corrected metrics. In a subset of patients with recurrent glioblastoma (n = 25), we determined receiver operating characteristic area under the curve for fractional tumor burden accuracy to predict the tissue diagnosis of tumor recurrence versus posttreatment effect. We also determined correlations between rCBV and microvessel area from stereotactic biopsies (n = 29) in 12 patients. RESULTS: With IB Neuro, relative CBV metrics correlated highly between non-preload dose- and preload dose-corrected conditions for fractional tumor burden (r = 0.96, ρ = 0.94), percentage > 1.75 (r = 0.93, ρ = 0.91), mean (r = 0.87, ρ = 0.86), and mode (r = 0.78, ρ = 0.76). These correlations dropped substantially with nordicICE. With fractional tumor burden, IB Neuro was more accurate than nordicICE in diagnosing tumor versus posttreatment effect (area under the curve = 0.85 versus 0.67) (P < .01). The highest relative CBV-microvessel area correlations required preload dose and IB Neuro (r = 0.64, ρ = 0.58, P = .001). CONCLUSIONS: Different implementations of perfusion MR imaging software modeling can impact the accuracy of leakage correction, relative CBV calculation, and correlations with histologic benchmarks.
Authors: A Kassner; D J Annesley; X P Zhu; K L Li; I D Kamaly-Asl; Y Watson; A Jackson Journal: J Magn Reson Imaging Date: 2000-02 Impact factor: 4.813
Authors: Kathleen M Schmainda; Scott D Rand; Allen M Joseph; Rebecca Lund; B Doug Ward; Arvind P Pathak; John L Ulmer; Michael A Badruddoja; Michael A Baddrudoja; Hendrikus G J Krouwer Journal: AJNR Am J Neuroradiol Date: 2004-10 Impact factor: 3.825
Authors: Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez Journal: AJNR Am J Neuroradiol Date: 2004-02 Impact factor: 3.825
Authors: Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag Journal: AJNR Am J Neuroradiol Date: 2003 Nov-Dec Impact factor: 3.825
Authors: K M Schmainda; M A Prah; S D Rand; Y Liu; B Logan; M Muzi; S D Rane; X Da; Y-F Yen; J Kalpathy-Cramer; T L Chenevert; B Hoff; B Ross; Y Cao; M P Aryal; B Erickson; P Korfiatis; T Dondlinger; L Bell; L Hu; P E Kinahan; C C Quarles Journal: AJNR Am J Neuroradiol Date: 2018-05-24 Impact factor: 3.825
Authors: J M Hoxworth; J M Eschbacher; A C Gonzales; K W Singleton; G D Leon; K A Smith; A M Stokes; Y Zhou; G L Mazza; A B Porter; M M Mrugala; R S Zimmerman; B R Bendok; D P Patra; C Krishna; J L Boxerman; L C Baxter; K R Swanson; C C Quarles; K M Schmainda; L S Hu Journal: AJNR Am J Neuroradiol Date: 2020-03-12 Impact factor: 3.825
Authors: L S Hu; H Yoon; J M Eschbacher; L C Baxter; A C Dueck; A Nespodzany; K A Smith; P Nakaji; Y Xu; L Wang; J P Karis; A J Hawkins-Daarud; K W Singleton; P R Jackson; B J Anderies; B R Bendok; R S Zimmerman; C Quarles; A B Porter-Umphrey; M M Mrugala; A Sharma; J M Hoxworth; M G Sattur; N Sanai; P E Koulemberis; C Krishna; J R Mitchell; T Wu; N L Tran; K R Swanson; J Li Journal: AJNR Am J Neuroradiol Date: 2019-02-28 Impact factor: 3.825
Authors: Jerrold L Boxerman; Chad C Quarles; Leland S Hu; Bradley J Erickson; Elizabeth R Gerstner; Marion Smits; Timothy J Kaufmann; Daniel P Barboriak; Raymond H Huang; Wolfgang Wick; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Caroline Chung; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert; Bruce R Rosen; Benjamin M Ellingson; Kathleen M Schmainda Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Manuel Alexander Schmidt; Michael Knott; Philip Hoelter; Tobias Engelhorn; Elna Marie Larsson; Than Nguyen; Marco Essig; Arnd Doerfler Journal: Br J Radiol Date: 2019-10-24 Impact factor: 3.039
Authors: Ramon F Barajas; Letterio S Politi; Nicoletta Anzalone; Heiko Schöder; Christopher P Fox; Jerrold L Boxerman; Timothy J Kaufmann; C Chad Quarles; Benjamin M Ellingson; Dorothee Auer; Ovidiu C Andronesi; Andres J M Ferreri; Maciej M Mrugala; Christian Grommes; Edward A Neuwelt; Prakash Ambady; James L Rubenstein; Gerald Illerhaus; Motoo Nagane; Tracy T Batchelor; Leland S Hu Journal: Neuro Oncol Date: 2021-07-01 Impact factor: 12.300